BioXcel Therapeutics, Inc.
BTAI
$1.17
-$0.02-1.68%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -30.05% | -54.21% | -89.13% | -71.13% | -2.66% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -30.05% | -54.21% | -89.13% | -71.13% | -2.66% |
| Cost of Revenue | -96.15% | -99.06% | 72.58% | -82.50% | 16.53% |
| Gross Profit | 148.07% | 109.10% | -98.75% | -69.32% | -37.87% |
| SG&A Expenses | -7.06% | -29.96% | -40.65% | -57.03% | -57.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.67% | 1.28% | -8.96% | -58.51% | -46.54% |
| Operating Income | 1.71% | -2.14% | 3.58% | 58.20% | 47.37% |
| Income Before Tax | -15.53% | -126.45% | -131.20% | 72.92% | 51.21% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.53% | -126.45% | -131.20% | 72.92% | 51.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.53% | -126.45% | -131.20% | 72.92% | 51.21% |
| EBIT | 1.71% | -2.14% | 3.58% | 58.20% | 47.37% |
| EBITDA | 1.69% | -2.17% | 3.58% | 58.38% | 47.55% |
| EPS Basic | 83.94% | 57.74% | 25.83% | 89.20% | 70.45% |
| Normalized Basic EPS | 83.89% | 52.62% | 17.30% | 89.20% | 70.54% |
| EPS Diluted | 83.94% | 57.74% | 25.83% | 89.20% | 70.45% |
| Normalized Diluted EPS | 83.89% | 52.62% | 17.30% | 89.20% | 70.54% |
| Average Basic Shares Outstanding | 619.18% | 435.90% | 211.72% | 150.60% | 65.11% |
| Average Diluted Shares Outstanding | 619.18% | 435.90% | 211.72% | 150.60% | 65.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |